RecruitingPhase 2NCT06467617

Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC

Studying Chronic bilirubin encephalopathy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Beijing Chest Hospital, Capital Medical University
Principal Investigator
Jinghui Wang
Director of Research Laboratory, Beijing Chest Hospital
Intervention
Adebrelimab plus albumin-bound paclitaxel, carboplatin and recaticimab(drug)
Enrollment
35 target
Eligibility
18-75 years · All sexes
Timeline
20242027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06467617 on ClinicalTrials.gov

Other trials for Chronic bilirubin encephalopathy

Additional recruiting or active studies for the same condition.

See all trials for Chronic bilirubin encephalopathy

← Back to all trials